Clinical activity and safety of naptumomab and docetaxel to be presented at ASCO 2024
May 28, 2024
News
Active Biotech acquires exclusive rights to patents of tasquinimod in combination therapy
May 22, 2024
Active Biotech announces start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops
April 3, 2024
Positive preclinical tasquinimod data presented at ASH 2023 now available on Active Biotech’s website
December 14, 2023
Active Biotech enters into collaboration agreement for clinical ocular biodistribution study with laquinimod
December 5, 2023
Lead Principal Investigator Rebekka Schneider-Kramann presents the clinical plan and positioning of tasquinimod in myelofibrosis
December 1, 2023
Management and members of the board of directors have subscribed for shares in Active Biotech’s ongoing rights issue
November 29, 2023
Preclinical data of tasquinimod in myelofibrosis awarded oral presentation at ASH 2023
November 2, 2023
Active Biotech presentation at Aktiespararnas “Aktiedag Lund”, October 9, 2023 (in Swedish)
October 10, 2023
Clinical safety and preclinical ocular biodistribution for laquinimod eye drops presented at the IOIS meeting available at Active Biotech’s website
September 13, 2023
Tasquinimod successfully completes dose optimization in patients with multiple myeloma and advances into the pre-planned expansion cohort
September 11, 2023
Active Biotech enters into clinical trial collaboration agreement for a clinical study with tasquinimod in myelofibrosis
August 1, 2023
Safety and ocular biodistribution support development of laquinimod eye drops for inflammatory eye disorders
May 30, 2023
New preclinical data on the antifibrotic effects of tasquinimod in myelofibrosis to be presented at EHA 2023
May 12, 2023
NeoTX poster from the American Association for Cancer Research (AACR) Annual Meeting is now available
April 19, 2023
Safety and preliminary activity of naptumomab in combination with durvalumab presented at AACR 2023
April 19, 2023
Two recent publications describe the mechanisms by which tasquinimod can act as a potential treatment alternative in multiple myeloma
March 16, 2023